These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1275 related items for PubMed ID: 14659138

  • 21. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA, Aksoy S, Zengin N, Altundag K.
    J BUON; 2013 Jan 01; 18(4):838-44. PubMed ID: 24344006
    [Abstract] [Full Text] [Related]

  • 24. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec 01; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5108-16. PubMed ID: 15998903
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C.
    Am J Clin Oncol; 2003 Aug 01; 26(4):S9-16. PubMed ID: 12902872
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A decade of letrozole: FACE.
    O'Shaughnessy J.
    Breast Cancer Res Treat; 2007 Aug 01; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [Abstract] [Full Text] [Related]

  • 33. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS.
    Breast; 2006 Feb 01; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [Abstract] [Full Text] [Related]

  • 38. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT, Carlson RW.
    Clin Breast Cancer; 2004 Sep 01; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.